Otsuka Pharmaceutical Co., Ltd.

This study tests the safety of a daily medication called EB-1020 for children and teenagers with ADHD over 52 weeks. About 180 participants in Japan and China will take the drug once daily. The main goal is to see how many experience side effects during long-term use.

This study monitors the safety of the drug LUPKYNIS in 400 people with lupus nephritis who are just starting the medication. Researchers will track side effects and also collect information on how well the drug works in everyday use. The goal is to understand real-world risks and…

This study is testing a new medication called SEP-363856 in 100 adults with schizophrenia who are already stable on their current treatment. The goal is to see how safe and tolerable the drug is when taken for a full year. Participants will take either 75 mg or 100 mg daily, and …

This study tests a new medication called EB-1020, taken once daily as a capsule, to see if it safely reduces ADHD symptoms in children and adolescents aged 6-17. About 315 participants will be randomly assigned to receive a low dose, high dose, or placebo for 6 weeks. The main go…